Back to top
more

Agenus (AGEN)

(Delayed Data from NSDQ)

$10.78 USD

10.78
355,469

+0.08 (0.75%)

Updated May 15, 2024 04:00 PM ET

After-Market: $10.74 -0.04 (-0.37%) 6:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab

by Zacks Equity Research

Agenus (AGEN) initiates the rolling submission of its BLA to the FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.

Agenus (AGEN) in Focus: Stock Moves 7.6% Higher

by Zacks Equity Research

Agenus (AGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -3.70% and 188.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Can Trikafta Drive Vertex's (VRTX) Revenues in Q2 Earnings?

by Zacks Equity Research

On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the sales performance of its newly-launched CF drug Trikafta and the anticipated impact of COVID-19 on sales.

What to Expect for Applied Therapeutics (APLT) Q2 Earnings

by Zacks Equity Research

During Applied Therapeutics' (APLT) upcoming Q2 earnings call, investor focus will be on the company's progress with its novel pipeline candidates targeting areas of high unmet medical need.

Is a Beat in Store for Translate Bio (TBIO) in Q2 Earnings?

by Zacks Equity Research

On Translate Bio's (TBIO) Q2 earnings call, investor focus will be on the company's progress with the development of its multiple COVID-19 vaccine candidates in collaboration with Sanofi.

Alimera (ALIM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.

Gamida Cell (GMDA) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Gamida Cell (GMDA) will provide updates on its pipeline candidates when it releases second-quarter 2020 results.

Innoviva (INVA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

During Innoviva's (INVA) upcoming Q2 earnings call, investor focus will be on the royalties earned that comprise the company's top line.

Agenus (AGEN) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Moving Average Crossover Alert: Agenus

by Zacks Equity Research

Agenus Inc. (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

What Makes Agenus (AGEN) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AGEN) Outperforming Other Medical Stocks This Year?

Agenus' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Agenus.

Agenus Stock Up on Licensing Deal With China-Based Firm

by Zacks Equity Research

Agenus (AGEN) signs an exclusive collaboration and license agreement with Chinese company, Betta Pharmaceuticals, for the development and commercialization of balstilimab and zalifrelimab.

Why Is Agenus (AGEN) Up 51.6% Since Last Earnings Report?

by Zacks Equity Research

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2%

by Zacks Equity Research

Intellia Therapeutics (NTLA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

Has Agenus (AGEN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (AGEN) Outperforming Other Medical Stocks This Year?

Is the Options Market Predicting a Spike in Agenus (AGEN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.

Protalix Submits BLA for Fabry Disease Candidate PRX-102

by Zacks Equity Research

Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.

Mersana Stock Spikes on Interim Data on Cancer Candidate

by Zacks Equity Research

Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.

Ironwood to Halt MD-7246 Development After Study Failure

by Zacks Equity Research

Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.

Agenus' (AGEN) IND for iNKT Therapy Gets FDA Acceptance

by Zacks Equity Research

The FDA clears Agenus' (AGEN) IND application for allogeneic iNKT therapy, agenT-797, which is being developed to treat cancer as well as the deadly COVID-19 pandemic.

Agenus (AGEN): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

Agenus (AGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.